List of Excipients in Branded Drug ALENDRONATE SODIUM

Generic Drugs Containing ALENDRONATE SODIUM

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	alendronate sodium	0054-0282	ANHYDROUS CITRIC ACID
Hikma Pharmaceuticals USA Inc	alendronate sodium	0054-0282	METHYLPARABEN
Hikma Pharmaceuticals USA Inc	alendronate sodium	0054-0282	PROPYLPARABEN
Hikma Pharmaceuticals USA Inc	alendronate sodium	0054-0282	SACCHARIN SODIUM
Hikma Pharmaceuticals USA Inc	alendronate sodium	0054-0282	SODIUM CITRATE
Amneal Pharmaceuticals of New York LLC	alendronate sodium	0115-1676	CELLULOSE, MICROCRYSTALLINE
Amneal Pharmaceuticals of New York LLC	alendronate sodium	0115-1676	CROSCARMELLOSE SODIUM

What are the Most Frequently-Used Excipients in ALENDRONATE SODIUM?

# Of NDCs	Excipient
3	ANHYDROUS CITRIC ACID
38	CELLULOSE, MICROCRYSTALLINE
12	CROSCARMELLOSE SODIUM
5	LACTOSE MONOHYDRATE
38	MAGNESIUM STEARATE
14	MANNITOL
3	METHYLPARABEN

Alendronate Sodium Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Alendronate sodium is a mature, highly genericized bisphosphonate with limited active-ingredient patent protection but continuing formulation opportunities. Commercial value is concentrated in excipient systems that improve dosing convenience, tablet robustness, dissolution, taste, gastrointestinal handling, adherence, and differentiation for osteoporosis patients.

The strongest opportunities are effervescent tablets, orally disintegrating or rapidly dispersing formats, lower-swallowing-burden products, combination products, and manufacturing platforms that reduce variability in a low-dose, highly water-soluble but poorly absorbed drug. Any reformulation must preserve the strict administration requirements that govern alendronate exposure and minimize esophageal contact.

What is the pharmaceutical formulation profile of alendronate sodium?

Alendronate sodium is the sodium salt of alendronic acid, used primarily for osteoporosis and other disorders of abnormal bone resorption. It is marketed in daily and weekly oral dosage forms, most commonly as tablets.

Attribute	Commercial relevance
Active ingredient	Alendronate sodium
Drug class	Aminobisphosphonate
Main indications	Postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis, Paget's disease
Common strengths	5 mg, 10 mg, 35 mg, 40 mg, and 70 mg
Common regimen	70 mg once weekly for osteoporosis
Oral bioavailability	Less than 1% under fasting conditions
Main absorption issue	Food, beverages, calcium, minerals, and other medicines substantially reduce absorption
Main tolerability issue	Esophageal irritation and upper gastrointestinal adverse effects
Main formulation challenge	Delivering a low dose with consistent dissolution while minimizing local mucosal exposure

The FDA label instructs patients to take alendronate after overnight fasting with plain water and to remain upright for at least 30 minutes. Food, mineral water, calcium, antacids, and other oral medicines must be separated from dosing because they can reduce absorption.[1]

This creates a narrow excipient design window. Excipients must support rapid dispersion and reproducible release without encouraging administration with food, juice, milk, coffee, or mineral-containing beverages.

What excipients are used in alendronate sodium tablets?

Conventional alendronate tablets typically use a relatively standard direct-compression or wet-granulation excipient system. Reference-product labeling identifies excipients such as microcrystalline cellulose, lactose anhydrous, croscarmellose sodium, and magnesium stearate for certain Fosamax tablet strengths.[1]

Core excipient functions

Excipient function	Typical candidates	Strategic purpose
Diluent	Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate	Controls tablet mass and compressibility
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Promotes rapid tablet breakup
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces ejection force and tooling adhesion
Glidant	Colloidal silicon dioxide	Improves powder flow
Taste modifier	Sucralose, saccharin sodium, flavors	Supports dispersible or effervescent dosage forms
Effervescent acid	Citric acid, malic acid, fumaric acid	Generates carbon dioxide and improves dispersion
Effervescent base	Sodium bicarbonate, potassium bicarbonate	Controls effervescence and pH
Wetting agent	Poloxamer, sodium lauryl sulfate, polysorbate	Can improve wetting and dissolution, subject to tolerability limits
Film coating	Hypromellose, polyethylene glycol, titanium dioxide or permitted alternatives	Improves handling, identification, and swallowability

The most important variables are not the number of excipients but their effect on dissolution, pH, moisture sensitivity, compressibility, and product stability.

What excipient strategies improve alendronate performance?

Rapid-disintegration tablets

Rapid-disintegration tablets can reduce the time that an intact tablet remains in contact with the esophageal mucosa. A high-efficiency disintegrant system based on croscarmellose sodium or crospovidone can support rapid breakup in water.

The formulation must avoid excessive hardness or hydrophobic lubrication. High magnesium stearate levels, over-lubrication, and excessive compression force can delay wetting and dissolution. A design using lower lubricant concentration, controlled blending time, and optimized tablet porosity can improve release consistency.

Commercial positioning would focus on:

• Easier swallowing
• Lower pill burden
• Reduced tablet residence time
• Improved acceptance among older patients
• Differentiation from standard generic tablets

The product cannot imply that faster disintegration removes the need for upright posture or fasting unless supported by clinical and regulatory evidence.

Effervescent tablets

Effervescent alendronate products are the clearest example of excipient-led differentiation. Binosto, a branded effervescent alendronate product, is dissolved in water before administration rather than swallowed as an intact tablet.[2]

Effervescence can provide several benefits:

1. It converts a solid tablet into a dispersed oral dose.
2. It improves palatability through flavor and sweetener systems.
3. It may reduce direct contact between a solid tablet and the esophageal lining.
4. It creates a differentiated administration experience in a genericized market.

The technical risks are substantial. Effervescent systems are sensitive to moisture ingress, packaging integrity, acid-base balance, residual water, and carbon dioxide loss. Suitable packaging may require high-barrier aluminum blister packs, desiccants, or tube systems with moisture-control features.

The formulation must also control sodium load. Alendronate sodium is already a sodium-containing active ingredient, and sodium bicarbonate may materially increase total sodium content. This issue can affect labeling, patient selection, and international marketability.

Orally disintegrating and orally dispersible formats

An orally disintegrating tablet could address swallowing difficulty, but alendronate's administration instructions complicate development. The dose still must be taken with an adequate volume of plain water, and the patient must remain upright. A product that dissolves in the mouth may expose the oral mucosa to a highly charged phosphonate compound and may have poor palatability.

An orally dispersible tablet designed to be mixed with water is more technically credible than a tablet intended to dissolve on the tongue. The main excipient requirements are rapid dispersion, low residual particulate load, controlled taste, and compatibility with blister packaging.

Taste-masked liquid or suspension formulations

Liquid formulations could help patients who cannot swallow tablets. The commercial case is weaker because the active ingredient must still be taken fasting and separated from calcium-containing or mineral-containing liquids.

A liquid product would require:

• Uniform dose delivery after shaking
• Chemical and microbial stability
• Low sedimentation or rapid redispersion
• Taste masking
• A calibrated dosing device
• Packaging that limits adsorption and contamination

Chelating or mineral-containing excipients should be avoided because alendronate has strong affinity for divalent and trivalent cations. Calcium, magnesium, aluminum, and iron can form poorly absorbed complexes.

What formulation patents protect alendronate sodium products?

The principal alendronate compound and early product patents are expired or no longer commercially decisive in the United States. The current competitive landscape is dominated by abbreviated new drug applications, legacy formulation patents, manufacturing know-how, trademarks, and product-specific regulatory positioning.

The key protected areas historically included:

• Alendronate compound and salt chemistry
• Oral dosage forms
• Weekly dosing regimens
• Effervescent dosage forms
• Manufacturing and granulation processes
• Treatment methods for osteoporosis and Paget's disease

A reformulator should distinguish between three types of protection:

Protection type	Current strategic value
Expired compound patents	Minimal blocking value
Expired or weak formulation patents	Limited barrier unless narrowly practiced
New formulation patents	Potential value if supported by comparative performance, stability, adherence, or clinical data

A new patent strategy would have greater value if it claims a specific excipient ratio, moisture-control architecture, dissolution profile, taste-masking system, or manufacturing process tied to measurable product performance. Broad claims to “an alendronate tablet with pharmaceutically acceptable excipients” are unlikely to provide strong protection in a crowded generic field.

When does alendronate sodium lose exclusivity?

Alendronate sodium lost practical small-molecule exclusivity years ago. Fosamax was approved by the FDA in 1995, and generic alendronate products have been marketed for many years.[3] Weekly 70 mg products also have extensive generic competition.

Milestone	Date or status
Fosamax U.S. approval	1995
Generic alendronate market	Established
Compound exclusivity	Expired
Conventional tablet patent barrier	No longer commercially controlling
Biosimilar pathway	Not applicable
Current opportunity	Formulation, delivery, packaging, adherence, and manufacturing differentiation

The absence of meaningful compound exclusivity does not eliminate commercial opportunity. It changes the investment thesis from monopoly pricing to differentiated generic, branded-generic, private-label, licensing, or contract-manufacturing economics.

What is the Orange Book status of alendronate sodium?

The FDA Orange Book lists approved alendronate products and their therapeutic equivalence information. Conventional alendronate tablets are generally marketed through abbreviated new drug applications and compete on generic substitution, price, supply reliability, and dosage-form availability.[4]

Orange Book analysis should focus on:

• Active listed products
• Therapeutic-equivalence codes
• Reference-listed drug status
• Any remaining patent or exclusivity listing
• Differences between tablet and effervescent products
• Whether a proposed product is substitutable or requires a new drug application

An effervescent product may not receive the same practical substitution dynamics as a conventional tablet if its dosage form, labeling, or reference product relationship differs. That distinction can create a commercial niche even where conventional tablets are fully commoditized.

Which companies are challenging alendronate sodium products?

Generic alendronate is supplied by multiple manufacturers and marketing partners. Depending on market and time period, suppliers have included large generic companies and private-label distributors such as Teva, Mylan or Viatris, Sandoz, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, Apotex, and other regional manufacturers.

The competitive threat is primarily price-based rather than patent-based. Companies compete through:

• Lowest-cost active pharmaceutical ingredient sourcing
• High-yield tablet manufacturing
• Reliable supply to wholesalers and public payers
• Multiple strengths and pack sizes
• Effervescent or differentiated dosage forms
• Private-label distribution
• Regulatory compliance and shortage avoidance

Company participation varies by strength, country, and procurement channel. A product-level market review should use current FDA, EMA, national marketing authorization, and commercial sales data rather than assume that every manufacturer supplies every strength.

What Paragraph IV challenges and litigation affect alendronate sodium?

Paragraph IV litigation was more commercially relevant during the launch of generic Fosamax and other early generic products. For a mature alendronate market, current litigation risk is more likely to arise from a newly differentiated formulation, method-of-use claim, manufacturing process, or trademark issue than from the basic active ingredient.

Potential litigation categories include:

• ANDA patent challenges against any still-listed formulation claims
• Patent infringement claims involving effervescent compositions
• Product liability claims involving esophageal injury
• Antitrust or settlement scrutiny involving generic entry
• Trade dress and trademark disputes
• Contract disputes involving API supply or private-label rights

A new applicant should conduct a current Orange Book patent certification analysis and a broader freedom-to-operate review covering U.S. patents that may not be listed in the Orange Book, including process and packaging patents.

Are biosimilar risks relevant to alendronate sodium?

No. Alendronate sodium is a chemically synthesized small molecule, not a biologic. Biosimilar approval pathways do not apply.

The relevant competitive pathways are:

• ANDA approval for conventional generic products
• A 505(b)(2) application for a materially different dosage form, delivery system, or clinical use
• Full new drug application development for a clinically differentiated product

A reformulated effervescent or liquid product may fit a 505(b)(2) strategy if it relies partly on published literature or the reference product while introducing a meaningful change in formulation or administration.

What manufacturing and intellectual-property barriers matter?

The active ingredient is not the main barrier. The important barriers are process control, stability, dissolution, and packaging.

API and process considerations

Alendronate sodium is highly polar and can present handling challenges during blending and granulation. Developers should evaluate:

• Particle-size distribution
• Bulk density and flow
• Hydrate or water-content control
• Electrostatic behavior
• Blend uniformity at low dose
• Residual solvent and elemental impurity profile
• Compatibility with excipients
• Scale-up effects on dissolution

For a 5 mg or 10 mg product, content uniformity is a central manufacturing issue. For a 70 mg product, tablet size, hardness, swallowability, and dose uniformity remain important.

Effervescent manufacturing barriers

Effervescent products require tighter environmental controls than conventional tablets. The main risks are:

• Premature acid-base reaction
• Moisture-driven potency or dissolution changes
• Tablet softening or swelling
• Carbon dioxide loss
• Packaging failure
• Flavor degradation
• Variable dispersion time

These conditions can create protectable process know-how even when patent protection is narrow.

What commercial opportunities exist for alendronate sodium excipients?

Branded generic or authorized generic

A manufacturer can use a conventional tablet with improved mechanical strength, reduced friability, smaller tablet dimensions, or more convenient packaging. Price premiums will be limited unless the product secures payer, pharmacy, or patient preference.

Effervescent product licensing

Effervescent alendronate is the most visible licensing opportunity. A company with a validated formulation, stable moisture-barrier package, and regulatory dossier could license:

• Regional marketing rights
• A 505(b)(2) application
• A finished-dose manufacturing platform
• A private-label product
• An authorized generic arrangement

The commercial value depends on whether the product can obtain differentiated reimbursement and avoid direct substitution pressure.

Excipient supplier partnerships

Excipient companies can target:

• Direct-compression grades of microcrystalline cellulose
• High-performance superdisintegrants
• Low-moisture excipient systems
• Taste-masking technologies
• Effervescent acid-base platforms
• Moisture-barrier packaging
• Continuous manufacturing and process analytical technology

The strongest proposition is a complete formulation and packaging solution, not a single commodity excipient.

Combination products

Alendronate has been marketed in combination with vitamin D. Combination products may improve regimen convenience but create compatibility and labeling challenges. Calcium is generally unsuitable in the same immediate-release product because it can bind alendronate and reduce absorption.

A combination with vitamin D is more technically feasible, but the product must maintain content uniformity, stability, and administration instructions that prevent coadministration with calcium-containing foods or supplements.

Specialty adherence programs

Weekly dosing already reduces pill burden compared with daily dosing. Commercial programs can add value through:

• Calendar blister packaging
• Reminder-enabled packaging
• Patient education
• Easy-open but moisture-resistant packs
• Integrated vitamin D adherence support
• Pharmacy synchronization

These are commercial and packaging differentiators rather than core patent opportunities.

How strong is the alendronate sodium patent estate?

The estate is weak for the basic molecule and conventional tablets but can be moderate for narrow, well-supported formulation claims.

Area	Patent strength	Commercial assessment
Active ingredient	Low	Mature and genericized
Standard immediate-release tablet	Low	Heavy price competition
Weekly dosing concept	Low	Historically important, now established
Effervescent formulation	Moderate if narrowly claimed	Best differentiated dosage-form opportunity
Taste masking	Moderate	Requires measurable performance advantage
Moisture-barrier packaging	Moderate	More likely to protect know-how and system claims
Manufacturing process	Moderate	Scale-up and reproducibility can create barriers
Adherence packaging	Low to moderate	Commercially useful but easy to design around
Combination with vitamin D	Low to moderate	Regulatory and formulation execution matter more than broad patent scope

Patent strength should be assessed claim by claim. A narrow claim supported by comparative dissolution, stability, palatability, or clinical adherence data can have more commercial value than a broad but predictable excipient claim.

What generic launch scenarios exist for alendronate sodium?

Scenario 1: Conventional low-cost generic

This is the lowest-risk pathway but has the weakest margin profile. Success depends on manufacturing cost, supply reliability, and procurement scale.

Scenario 2: Smaller or easier-to-swallow tablet

This approach can target older patients and patients with dysphagia. The product must demonstrate acceptable dose uniformity, dissolution, stability, and patient usability.

Scenario 3: Effervescent alendronate

This has the strongest product differentiation. The major risks are development cost, packaging, sodium content, regulatory pathway, and limited reimbursement premium.

Scenario 4: 505(b)(2) dispersible product

A water-dispersible tablet may offer a balance between differentiation and regulatory feasibility. Its value depends on whether the administration method produces a meaningful clinical or adherence advantage.

Scenario 5: Contract-manufactured private label

A finished-dose manufacturer can supply pharmacies, regional distributors, or health systems. This model reduces commercial investment but increases price pressure and dependence on procurement contracts.

How does alendronate sodium compare with other osteoporosis drugs?

Product class	Excipient and formulation opportunity	Competitive position
Alendronate sodium	Effervescent, dispersible, swallowability, packaging	Low-cost oral generic
Risedronate sodium	Delayed-release and dosing-interval differentiation	Competes on tolerability and regimen
Ibandronate sodium	Monthly oral or injectable dosing	Higher convenience, narrower use
Zoledronic acid	Intravenous infusion	Avoids oral absorption and esophageal exposure
Denosumab	Injectable biologic	Biosimilar and interchangeability issues apply
Teriparatide and related agents	Pen and device technology	Device and biologic formulation barriers
Romosozumab	Injectable biologic	Specialty pricing and biologic competition

Alendronate remains structurally disadvantaged in convenience but advantaged in cost and clinical familiarity. Excipient innovation can narrow the convenience gap without changing the active ingredient's low bioavailability.

What FDA regulatory issues govern alendronate excipient development?

The regulatory file must establish that the excipient system does not alter safety or efficacy in a clinically meaningful way. Key studies include:

• Assay and content uniformity
• Dissolution across relevant pH conditions
• Disintegration or dispersion time
• Stability under long-term and accelerated conditions
• Moisture uptake and package integrity
• Comparative bioavailability when required
• Food-effect assessment for materially changed products
• Palatability and usability for dispersible products
• Microbial quality for liquid products
• Extractables and leachables for specialized packaging

The label must preserve the core administration instructions unless clinical data support a change. A formulation that disperses in water still must be evaluated for the effects of water volume, standing time, temperature, and incomplete transfer from the glass.

Key Takeaways

• Alendronate sodium is a mature generic small molecule with no biosimilar pathway and limited active-ingredient patent protection.
• Conventional tablet excipients are commoditized; commercial value lies in performance, packaging, and regulatory differentiation.
• Effervescent alendronate is the strongest excipient-led opportunity because it changes administration and may improve swallowing and acceptability.
• Rapid-disintegration and water-dispersible products are viable development concepts, but they do not automatically remove fasting or upright-posture requirements.
• Calcium, magnesium, aluminum, iron, and other mineral-containing excipients can impair alendronate absorption and require strict compatibility review.
• Moisture control, acid-base stability, packaging integrity, and sodium content are central risks for effervescent products.
• A 505(b)(2) strategy may be more appropriate than a conventional ANDA for a materially different dosage form.
• Patent value is strongest in narrow formulation, process, packaging, and performance claims supported by comparative data.
• Generic launch economics depend more on manufacturing efficiency, supply reliability, reimbursement, and channel access than on legacy patent exclusivity.

FAQs

Can calcium be used as an excipient in alendronate sodium tablets?

Calcium is generally unsuitable because it can bind alendronate and reduce gastrointestinal absorption. A calcium-containing combination requires specific formulation and clinical justification.

Is mannitol a suitable excipient for alendronate sodium?

Mannitol can function as a diluent and improve mouthfeel in dispersible products. Its suitability depends on moisture content, compression behavior, dissolution impact, and compatibility with the selected dosage form.

Can alendronate sodium be formulated as a chewable tablet?

A chewable product is technically possible but commercially and clinically challenging because of taste, oral mucosal exposure, and the requirement to take the dose with plain water while remaining upright.

Does an effervescent alendronate product eliminate esophageal risk?

It may reduce contact between an intact tablet and the esophagus, but it does not eliminate risk. Administration instructions and post-dose posture remain important unless supported by product-specific clinical evidence.

What is the best excipient opportunity for a generic alendronate manufacturer?

The strongest opportunity is a moisture-stable effervescent or water-dispersible dosage form supported by robust packaging, palatability data, rapid dispersion, and a regulatory pathway that permits meaningful product differentiation.

References

1. U.S. Food and Drug Administration. (2024). Fosamax (alendronate sodium) prescribing information.
2. U.S. Food and Drug Administration. (2024). Binosto (alendronate sodium) prescribing information.
3. U.S. Food and Drug Administration. (1995). Fosamax approval history and product information.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2017). Guidance for industry: ANDAs for certain highly soluble, highly permeable drugs.
6. National Institute for Health and Care Excellence. (2022). Osteoporosis: Assessing the risk of fragility fracture. NICE guideline CG146.